195 related articles for article (PubMed ID: 16038645)
1. Myeloid growth factors clinical practice guidelines in oncology.
Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
[No Abstract] [Full Text] [Related]
2. Myeloid growth factors.
Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
J Natl Compr Canc Netw; 2009 Jan; 7(1):64-83. PubMed ID: 19176207
[No Abstract] [Full Text] [Related]
3. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
Lyman GH
J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
[TBL] [Abstract][Full Text] [Related]
4. New treatment options for managing chemotherapy-induced neutropenia.
Valley AW
Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S11-7. PubMed ID: 12166032
[TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations for the application of hematopoietic growth factors.
Greil R; Jost LM;
Ann Oncol; 2005; 16 Suppl 1():i80-2. PubMed ID: 15888768
[No Abstract] [Full Text] [Related]
6. Chemotherapy-induced neutropenia: new approaches to an old problem.
Ozer H
Semin Oncol; 2003 Aug; 30(4 Suppl 13):1-2. PubMed ID: 14508713
[No Abstract] [Full Text] [Related]
7. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
8. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
Ozer H; Armitage JO; Bennett CL; Crawford J; Demetri GD; Pizzo PA; Schiffer CA; Smith TJ; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Somerfield MR;
J Clin Oncol; 2000 Oct; 18(20):3558-85. PubMed ID: 11032599
[No Abstract] [Full Text] [Related]
9. Pegfilgrastim lowers side-effects of chemotherapy.
Sharma DC
Lancet Oncol; 2004 Aug; 5(8):461. PubMed ID: 15309779
[No Abstract] [Full Text] [Related]
10. Colony-stimulating factors for febrile neutropenia during cancer therapy.
Bennett CL; Djulbegovic B; Norris LB; Armitage JO
N Engl J Med; 2013 Mar; 368(12):1131-9. PubMed ID: 23514290
[TBL] [Abstract][Full Text] [Related]
11. Colony-stimulating factors for adjunctive therapy of infections in neutropenic cancer patients.
Mayordomo JI; Rivera F; Cortes-Funes H
Support Care Cancer; 1995 Jan; 3(1):84-5. PubMed ID: 7535169
[No Abstract] [Full Text] [Related]
12. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic growth factors for chemotherapy-induced neutropenia.
Yalçin S
Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202
[No Abstract] [Full Text] [Related]
14. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
15. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K
Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890
[TBL] [Abstract][Full Text] [Related]
16. Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?
Croockewit AJ; Koopmans PP; de Pauw BE
Clin Pharmacol Ther; 1996 Jan; 59(1):1-6. PubMed ID: 8549028
[No Abstract] [Full Text] [Related]
17. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors.
Ozer H
Curr Opin Hematol; 1996 Jan; 3(1):3-10. PubMed ID: 9372045
[TBL] [Abstract][Full Text] [Related]
18. The American Society of Clinical Oncology guideline program.
Winn RF; Smith TF
Pharm Pract Manag Q; 1996 Apr; 16(1):31-8. PubMed ID: 10157738
[No Abstract] [Full Text] [Related]
19. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.
Strassels SA; Dickson M; Norris LB; Bennett CL
J Natl Cancer Inst; 2013 Aug; 105(15):1072-3. PubMed ID: 23873406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
